Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Kalaris Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Kalaris Therapeutics, Inc.

ALVR KLRS

Kalaris Therapeutics, Inc.

About Kalaris Therapeutics, Inc.

AlloVir, Inc. is a biopharmaceutical company specializing in allogeneic, off-the-shelf virus-specific T cell (VST) therapies designed to restore immunity in immunocompromised patients at risk of life-threatening viral infections. Its proprietary platform develops multi-virus and single-virus targeted cell therapies for transplant recipients and patients with viral diseases. The company’s business model focuses on developing, manufacturing, and commercializing VST therapies through patented technology and strategic collaborations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Kalaris Therapeutics, Inc.

1
1
Kalaris Therapeutics, Inc. Kalaris Therapeutics Reports $10.9 Million Net Loss in Q1 2026 Amid Increased R&D Expenses

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Kalaris Therapeutics, Inc. Kalaris Therapeutics Reports Annual Financial Results for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Kalaris Therapeutics, Inc. Kalaris Therapeutics Reports Improved Financials and Advances Clinical Trials for TH103

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Kalaris Therapeutics, Inc. Kalaris Therapeutics Reports $21.5 Million Net Loss in First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Kalaris Therapeutics, Inc. Kalaris Therapeutics Reports $10.2 Million Net Loss Following AlloVir Merger

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Kalaris Therapeutics, Inc. AlloVir Reports $58.77 Million Net Loss for 2024, Announces Merger with Kalaris Therapeutics

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Kalaris Therapeutics, Inc. AlloVir Reports Reduced Operating Expenses, Net Losses, and Cash Increase in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments